<DOC>
	<DOCNO>NCT01118546</DOCNO>
	<brief_summary>Aspirin effective protecting patient coronary artery disease adverse cardiac event , potent `` antiplatelet agent '' . Some patient may develop history hypersensitivity aspirin treatment usually resume patient . We develop rapid procedure induce tolerance patient ( SILBERMAN et al , Am J CARDIOL 2005 ; 95:509-10 ) wish test whether aspirin effective antiplatelet agent patient history allergy aspirin undergo desensitization patient without history hypersensitivity</brief_summary>
	<brief_title>Physiopathology Rapid Aspirin Desensitization</brief_title>
	<detailed_description>Previous study allergology prove safety desensitization procedure allergic patient imperative indication medication . This tolerance state usually obtain cumbersome procedure require several hour day . We adapt successfully procedure patient acute coronary artery disease require urgent aspirin ( exclude ST elevation myocardial infarction ) ( SILBERMAN et al , Am J CARDIOL 2005 ; 95:509-10 ) . Patients history Aspirin NonSteroidal Anti-Inflammatory Drugs hypersensitivity appear alteration eicosanoid metabolism : drug trigger imbalance toward leucotriene pathway . This case-control study aim - evaluate desensitization therapy anti-aggregant effect aspirin particular patient : clinical outcome , PFA test , level urinary metabolite thromboxane A2 ( 11 dehydro thromboxane B2 ) also usual aggregation test . - ass VITRO basophil activation induce aspirin desensitization procedure flow cytometric cellular allergen test use basophil surface marker mediator ' dosage . Before challenge procedure test aim confirm clinically establish diagnosis hypersensitivity . After desensitization , test intend good ass efficiency induce tolerance , attempt identify predictor successful desensitization well identify potential cross reactivity NSAIDs.. This procedure indicate patient aspirin NSAID intolerance imperative cardiological indication aspirin , acute coronary syndrome , placement stent . The desensitization procedure must perform coronary care unit ; patient duly informed benefit risk challenge provide write informed consent . Desensitization consist rapidly escalate aspirin dose administration ad hoc aspirin capsule prepare hospital pharmacist . Blood urinary sample obtain hospital stay coronary desensitization care . An additional blood urine sample obtain 6 8 week later outpatient visit laboratory . Initial biological data compare two control group match age , gender type acute coronary syndrome : - Controls 1 : patient CAD aspirin , without history hypersensitivity - Controls 2 : patient without CAD , aspirin without history hypersensitivity .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>INCLUSION CRITERIA : Age &gt; 18 year Admitted Hospital BICHAT , Cardiology Patients aspirin NSAID intolerance due hypersensitivity Imperative cardiological indication aspirin , acute coronary syndrome , placement stent Written inform consent Patient health insurance coverage EXCLUSION CRITERIA : Ongoing ST elevation acute coronary syndrome Ongoing sign symptom hypersensitivity allergy ( asthma , urticaria , Quincke ' edema , allergic symptom )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>aspirin</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>hypersensitivity</keyword>
	<keyword>Platelet aggregation</keyword>
</DOC>